Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticoagulants | 5 | 2017 | 302 | 1.680 |
Why?
|
| beta-Alanine | 4 | 2014 | 12 | 1.630 |
Why?
|
| Benzimidazoles | 4 | 2014 | 32 | 1.610 |
Why?
|
| Education, Pharmacy | 4 | 2014 | 124 | 1.010 |
Why?
|
| Venous Thromboembolism | 3 | 2014 | 137 | 1.000 |
Why?
|
| Hemorrhage | 4 | 2014 | 271 | 0.870 |
Why?
|
| Students, Pharmacy | 4 | 2013 | 91 | 0.830 |
Why?
|
| Poison Control Centers | 2 | 2014 | 2 | 0.830 |
Why?
|
| Clinical Competence | 3 | 2013 | 249 | 0.660 |
Why?
|
| Vaccination | 2 | 2023 | 222 | 0.620 |
Why?
|
| Drug Monitoring | 2 | 2017 | 36 | 0.580 |
Why?
|
| Deprescriptions | 1 | 2018 | 3 | 0.570 |
Why?
|
| Proton Pump Inhibitors | 1 | 2018 | 27 | 0.560 |
Why?
|
| Curriculum | 5 | 2013 | 307 | 0.510 |
Why?
|
| Antithrombins | 1 | 2017 | 28 | 0.500 |
Why?
|
| Faculty, Medical | 1 | 2017 | 60 | 0.500 |
Why?
|
| Influenza, Human | 2 | 2017 | 101 | 0.470 |
Why?
|
| Students, Medical | 1 | 2017 | 102 | 0.470 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 110 | 0.470 |
Why?
|
| Warfarin | 2 | 2017 | 94 | 0.450 |
Why?
|
| Students, Dental | 1 | 2014 | 5 | 0.430 |
Why?
|
| Education, Dental | 1 | 2014 | 10 | 0.430 |
Why?
|
| Thiophenes | 1 | 2014 | 14 | 0.430 |
Why?
|
| Morpholines | 1 | 2014 | 28 | 0.430 |
Why?
|
| Humans | 23 | 2023 | 29202 | 0.420 |
Why?
|
| Thrombophilia | 1 | 2014 | 10 | 0.410 |
Why?
|
| Blood Coagulation | 2 | 2013 | 120 | 0.410 |
Why?
|
| Factor Xa Inhibitors | 1 | 2014 | 55 | 0.410 |
Why?
|
| Student Health Services | 1 | 2013 | 1 | 0.390 |
Why?
|
| Schools, Pharmacy | 1 | 2013 | 33 | 0.380 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 346 | 0.380 |
Why?
|
| Interprofessional Relations | 4 | 2017 | 68 | 0.370 |
Why?
|
| Learning | 2 | 2010 | 100 | 0.360 |
Why?
|
| Diuretics | 1 | 2011 | 13 | 0.350 |
Why?
|
| Thromboembolism | 1 | 2011 | 57 | 0.340 |
Why?
|
| Aged | 9 | 2023 | 5647 | 0.320 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2010 | 35 | 0.310 |
Why?
|
| Secondary Prevention | 1 | 2010 | 46 | 0.310 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 22 | 0.310 |
Why?
|
| Dabigatran | 3 | 2014 | 20 | 0.300 |
Why?
|
| Educational Measurement | 4 | 2014 | 142 | 0.260 |
Why?
|
| Aging | 1 | 2014 | 1041 | 0.250 |
Why?
|
| Time Factors | 4 | 2017 | 1619 | 0.240 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 384 | 0.230 |
Why?
|
| Pharmacists | 2 | 2017 | 74 | 0.220 |
Why?
|
| Female | 8 | 2017 | 15819 | 0.210 |
Why?
|
| Feedback | 2 | 2014 | 33 | 0.210 |
Why?
|
| Administration, Oral | 2 | 2017 | 191 | 0.210 |
Why?
|
| Streptococcus pneumoniae | 1 | 2023 | 29 | 0.190 |
Why?
|
| Faculty | 3 | 2013 | 62 | 0.170 |
Why?
|
| Male | 6 | 2017 | 14120 | 0.160 |
Why?
|
| Adult | 5 | 2017 | 8125 | 0.150 |
Why?
|
| Aged, 80 and over | 3 | 2014 | 2070 | 0.150 |
Why?
|
| Nephritis, Interstitial | 1 | 2018 | 2 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2010 | 250 | 0.140 |
Why?
|
| Fractures, Bone | 1 | 2018 | 46 | 0.140 |
Why?
|
| Clostridium Infections | 1 | 2018 | 72 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2011 | 316 | 0.130 |
Why?
|
| Insulin, Long-Acting | 1 | 2017 | 4 | 0.130 |
Why?
|
| Insulin Glargine | 1 | 2017 | 6 | 0.130 |
Why?
|
| Blood Coagulation Tests | 1 | 2017 | 27 | 0.130 |
Why?
|
| Influenza Vaccines | 1 | 2017 | 55 | 0.130 |
Why?
|
| Glycated Hemoglobin A | 1 | 2017 | 64 | 0.120 |
Why?
|
| Hypoglycemia | 1 | 2017 | 34 | 0.120 |
Why?
|
| Universities | 1 | 2017 | 128 | 0.120 |
Why?
|
| Medication Adherence | 1 | 2017 | 48 | 0.120 |
Why?
|
| Health Personnel | 1 | 2017 | 99 | 0.120 |
Why?
|
| Physicians | 1 | 2017 | 83 | 0.120 |
Why?
|
| Retrospective Studies | 2 | 2013 | 2659 | 0.120 |
Why?
|
| OX40 Ligand | 1 | 2015 | 16 | 0.120 |
Why?
|
| Homozygote | 1 | 2015 | 36 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 24 | 0.110 |
Why?
|
| Blood Glucose | 1 | 2017 | 310 | 0.110 |
Why?
|
| Problem Solving | 2 | 2013 | 28 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 414 | 0.110 |
Why?
|
| Prescription Drug Diversion | 1 | 2014 | 1 | 0.110 |
Why?
|
| Dosage Forms | 1 | 2014 | 5 | 0.110 |
Why?
|
| Drug and Narcotic Control | 1 | 2014 | 7 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 84 | 0.110 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 20 | 0.110 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2014 | 28 | 0.110 |
Why?
|
| Pharmacies | 1 | 2014 | 19 | 0.110 |
Why?
|
| Medication Errors | 1 | 2014 | 26 | 0.110 |
Why?
|
| Drug Prescriptions | 1 | 2014 | 46 | 0.110 |
Why?
|
| Rivaroxaban | 1 | 2014 | 29 | 0.100 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 78 | 0.100 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2013 | 14 | 0.100 |
Why?
|
| Teaching | 1 | 2014 | 84 | 0.100 |
Why?
|
| Recurrence | 1 | 2014 | 328 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2013 | 69 | 0.100 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 126 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 1021 | 0.100 |
Why?
|
| Problem-Based Learning | 1 | 2013 | 62 | 0.100 |
Why?
|
| Diphosphonates | 1 | 2013 | 15 | 0.100 |
Why?
|
| Program Development | 2 | 2010 | 88 | 0.090 |
Why?
|
| Child | 3 | 2015 | 2354 | 0.090 |
Why?
|
| Health Occupations | 2 | 2009 | 9 | 0.090 |
Why?
|
| Kidney | 1 | 2014 | 290 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2013 | 271 | 0.090 |
Why?
|
| Osteoporosis | 1 | 2013 | 63 | 0.090 |
Why?
|
| International Normalized Ratio | 1 | 2011 | 27 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2011 | 79 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2013 | 903 | 0.080 |
Why?
|
| Receptors, CCR5 | 1 | 2010 | 4 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 155 | 0.080 |
Why?
|
| Bone Marrow Transplantation | 1 | 2010 | 49 | 0.080 |
Why?
|
| Tissue Donors | 1 | 2010 | 29 | 0.080 |
Why?
|
| Education, Professional | 1 | 2009 | 5 | 0.080 |
Why?
|
| Staff Development | 1 | 2009 | 9 | 0.080 |
Why?
|
| Program Evaluation | 1 | 2010 | 176 | 0.070 |
Why?
|
| Haplotypes | 1 | 2010 | 290 | 0.070 |
Why?
|
| Risk Factors | 1 | 2014 | 2144 | 0.070 |
Why?
|
| Oklahoma | 1 | 2011 | 1063 | 0.070 |
Why?
|
| Middle Aged | 3 | 2015 | 7493 | 0.060 |
Why?
|
| Vaccines, Conjugate | 1 | 2023 | 3 | 0.050 |
Why?
|
| Pneumococcal Vaccines | 1 | 2023 | 20 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 236 | 0.050 |
Why?
|
| Infant | 2 | 2015 | 1066 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2015 | 1213 | 0.040 |
Why?
|
| Oncogene Proteins v-myb | 1 | 2015 | 2 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2015 | 61 | 0.030 |
Why?
|
| Adolescent | 2 | 2015 | 3254 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2015 | 140 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 433 | 0.030 |
Why?
|
| Group Processes | 1 | 2013 | 8 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 741 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 288 | 0.020 |
Why?
|
| Bisphosphonate-Associated Osteonecrosis of the Jaw | 1 | 2013 | 3 | 0.020 |
Why?
|
| Femoral Fractures | 1 | 2013 | 10 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 557 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2013 | 41 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2010 | 13 | 0.020 |
Why?
|
| Students, Health Occupations | 1 | 2009 | 10 | 0.020 |
Why?
|
| Professional Competence | 1 | 2009 | 38 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 303 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2013 | 405 | 0.020 |
Why?
|
| Young Adult | 1 | 2010 | 2875 | 0.010 |
Why?
|